1. Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort
- Author
-
Postorino, M. C, Prosperi, M., QUIROS ROLDAN, Maria Eugenia, Maggiolo, F., Di Giambenedetto, S., Saracino, A., Costarelli, S., Lorenzotti, S., Sighinolfi, L., Di Pietro, M., Torti, Carlo, Castelli, Francesco, Carosi, Giampiero, Nasta, Paola, Paraninfo, G., Foca', Emanuele, Torti, C., Cauda, R., Fabbiani, M., Colafigli, M., Scalzini, Alfredo, Castelnuovo, F., Mazzotta, F., Locaputo, S., Marino, N., Pierotti, P., Ble, C., Vichi, F., Angarano, G., Ladisa, N., Monno, L., Maggi, Paolo, Pan, A., Gori, A., Lapadula, G., Ospedale, S., Puoti, M., Viale, P., Colangeli, V., Borderi, M., Policlinico, S., Postorino, M. C., Prosperi, M., Quiros-Roldan, E., Maggiolo, F., Di Giambenedetto, S., Saracino, A., Costarelli, S., Lorenzotti, S., Sighinolfi, L., Di Pietro, M., Torti, C., Castelli, F., Carosi, G., Nasta, P., Paraninfo, G., Foca, E., Cauda, R., Fabbiani, M., Colafigli, M., Scalzini, A., Castelnuovo, F., Mazzotta, F., Locaputo, S., Marino, N., Pierotti, P., Ble, C., Vichi, F., Angarano, G., Ladisa, N., Monno, L., Maggi, P., Pan, A., Gori, A., Lapadula, G., Ospedale, S., Puoti, M., Viale, P., Colangeli, V., Borderi, M., and Policlinico, S.
- Subjects
Cyclopropanes ,Male ,AIDS event ,HIV Infections ,Cohort Studies ,chemistry.chemical_compound ,Antiretroviral Therapy, Highly Active ,HIV Infection ,Viral ,immunological response ,ritonavir-boosted protease inhibitors ,composite outcome ,virus diseases ,Lopinavir ,General Medicine ,Hepatitis C ,Middle Aged ,Viral Load ,non-nucleoside reverse transcriptase inhibitors ,Death ,Ritonavir-boosted protease inhibitor ,Treatment Outcome ,Infectious Diseases ,Anti-Retroviral Agents ,Italy ,Alkynes ,Cohort ,RNA, Viral ,Female ,Viral load ,Human ,medicine.drug ,Cohort study ,Benzoxazine ,Adult ,Microbiology (medical) ,medicine.medical_specialty ,Efavirenz ,Atazanavir Sulfate ,virological response ,Antiretroviral Therapy ,Non-nucleoside reverse transcriptase inhibitor ,AIDS events ,Composite outcome ,Deaths ,First-line therapy ,Immunological response ,Non-nucleoside reverse transcriptase inhibitors ,Ritonavir-boosted protease inhibitors ,Virological response ,Benzoxazines ,CD4 Lymphocyte Count ,Humans ,Ritonavir ,Settore MED/17 - MALATTIE INFETTIVE ,first-line therapy ,Internal medicine ,medicine ,Highly Active ,business.industry ,Odds ratio ,medicine.disease ,deaths ,chemistry ,Immunology ,RNA ,Anti-Retroviral Agent ,Cohort Studie ,business - Abstract
Randomized trials and observational cohorts reported higher rates of virological suppression after highly active antiretroviral therapy (HAART) including efavirenz (EFV), compared with boosted protease inhibitors (PIs). Correlations with immunological and clinical outcomes are unclear. Patients of the Italian MASTER cohort who started HAART from 2000 to 2010 were selected. Outstanding outcome (composite outcome for success (COS)) was introduced. We evaluated predictors of COS (no AIDS plus CD4+ count >500/mm3 plus HIV-RNA
- Published
- 2015